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control at 12m was 48.4%. The median survival time was 30.9 
m for all patients. Delayed whole brain radiotherapy was 
needed in 13 patients. Applying univariate analysis no 
differences were observed either in BM volume, type of 
primary tumor, radiation doses, RPA and GPA indexes or time 
of presentation (synchronous vs. metachronous BM). One case 
of confirmed radiation necrosis was observed. 
Conclusions: Adjuvant RT after BM excision is safe, feasible 
and might avoid whole brain radiotherapy in a significant 
percentage of patients. We have not found differences 
between synchronous vs. metachronous presentation. 
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Purpose/Objective: Whole Lung Irradiation (WLI) is an option 
for pediatric Ewing Sarcoma (ES) with pulmonary metastases 
(PM) at time of diagnosis. At our institution, patients with 
Ewing's Sarcoma (ES) and PM at time of diagnosis are treated 
with WLI. The aim of this study was to analyze feasibility, 
overall survival and disease free survival in a homogeneous 
population.  
Materials and Methods: Seventeen patients were included in 
this retrospective, monocentric study. All patients underwent 
a local therapy on the site of primary tumor (surgery and/or 
radiation therapy) and a systemic treatment with induction 
chemotherapy (Vincristin, Adriamicin, Ifosfamide and 
Etoposide). Patients whose pulmonary metastases not 
responded at induction chemotherapy were 5 (29.4%), and 
underwent surgical resection of PM. All patients underwent 
systemic consolidation treatment with HDCT (Busulfan plus 
Melphalan) followed by WLI, that was administered by three 
dimensional (3D) conformal radiation therapy at dose of 15 
Gy in 10 fractions (fr) (in patients > 12 years old) or 12 Gy in 
10/fr (in pediatric patients). Patients demographics, fields of 
irradiation, local treatment and systemic treatment were 
collected. All patients were evaluated by clinical and 
radiological exams during the follow up. Duration of survival 
was defined as the time interval between diagnosis and death 
from any cause or most recent follow-up visit. Duration of 
disease free survival was defined as the time interval 
between diagnosis and disease recurrence or progression, 
death or most recent follow-up visit. 
Results: Mean age at time of diagnosis was 16.1 years (range 
7-34). The mean follow up time of surviving patients was 34.9 
months (range 10-84). The rate of pulmonary relapse (PR) 
was 52%. At 12, 24 and 36 months, DFS was 80.7%, 53.8% and 
40.3% and OS was 100%, 78% and 54.5%. Younger patients (< 
16 years old) had a higher survival (at 12, 24 and 36 months: 
100%, 100%, 85% vs 100%, 53.6 and 17.9%, respectively; 
p=0.005; Figure). Radiation pneumonitis developed in three 
patients at a median of 3 month (2,3,4 months) after WLI and 
was successfully treated with steroids. No clinically evident 
deterioration in pulmonary function was detected.  
 
Conclusions: Bilateral whole lung irradiation is a simple 
procedure with few acute or late sequelae. Our finding 
showed that pediatric patients had a higher survival. Further 
trials are necessary to define the WLI role in adults. 
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Purpose/Objective: Studies in advanced Hodgkin lymphoma 
(HL) suggest many relapses occur at the sites of initial 
disease, and have been used to justify the use of 
consolidative radiotherapy (RT). However, the chemotherapy 
regimens used in these studies vary from current practice and 
positron emission tomography (PET) was not used for 
assessment of stage or response. The aim of this study is to 
characterise patterns of relapse and survival outcomes in 
patients with PET staged advanced HL treated with the 
chemotherapy regimen of doxorubicin, bleomycin, vinblastine 
and dacarbazine (ABVD). 
Materials and Methods: Patients over 18 years old with 
newly diagnosed Stage III or IV HL treated with ABVD 
chemotherapy at our institution from January 2005 to 
December 2012 were included in this study. All patients were 
evaluated with PET prior to chemotherapy for staging and 
following chemotherapy to assess response. Patients were 
given consolidative RT at the discretion of treating clinicians. 
Patterns of relapse, disease-free survival (DFS) (measured 
from attainment of a complete response (CR) to disease 
recurrence or death), progression-free survival (PFS) 
(measured from first day of chemotherapy to lymphoma 
progression or death) and overall survival (OS) (measured 
